Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
Clinical trial NCT07483359 · RECRUITING
Trial details
- NCT number
- NCT07483359
- Sponsor
- First Hospital of China Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-20
- Primary completion
- 2027-06-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.